Novus Therapeutics Announces Acquisition of Anelixis Therapeutics
Acquisition includes lead clinical-stage compound AT-1501, a next generation anti-CD40L antibody, in development for organ and cellular transplantation, autoimmune diseases, and neurodegenerative diseases Senior management team with extensive drug development and...